Antibody Shows Encouraging Results for Treating High-risk Follicular Lymphoma and Marginal Zone Lymphoma
There’s good news on the treatment horizon for two typically slow-growing versions of lymphoma: follicular lymphoma and marginal zone lymphoma. Research presented by physicians from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, at the American Society of Hematology’s 2024 meeting in San Diego describes positive results for the antibody drug loncastuximab tesirine (Zynlonta) in patients with high-risk forms of these two blood cancers.